Institutional shares held 177 Million
229K calls
436K puts
Total value of holdings $4.78B
$6.18M calls
$11.8M puts
Market Cap $4.44B
164,254,000 Shares Out.
Institutional ownership 107.71%
# of Institutions 407


Latest Institutional Activity in ALKS

Top Purchases

Q2 2025
Oliver Luxxe Assets LLC Shares Held: 44.6K ($1.2M)
Q2 2025
Robeco Institutional Asset Management B.V. Shares Held: 113K ($3.06M)
Q2 2025
Abrdn PLC Shares Held: 179K ($4.83M)
Q2 2025
Assenagon Asset Management S.A. Shares Held: 84K ($2.27M)
Q2 2025
Health Invest Partners Ab Shares Held: 227K ($6.14M)

Top Sells

Q2 2025
Wealth Enhancement Advisory Services, LLC Shares Held: 12K ($325K)
Q2 2025
Us Bancorp \De\ Shares Held: 3.03K ($81.9K)
Q2 2025
Gamma Investing LLC Shares Held: 4.96K ($134K)
Q2 2025
Fifth Third Bancorp Shares Held: 1.12K ($30.2K)
Q2 2025
Parallel Advisors, LLC Shares Held: 282 ($7.62K)

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL for the treatment of alcohol and prevention of opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA to treat schizophrenia and schizoaffective; and VUMERITY for the treatment of relapsing forms of multiple sclerosis in adults, including clinically isolated syndrome, relapsing-remitting and active secondary progressive diseases. The company is also developing LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and nemvaleukin alfa, an engineered fusion protein to expand tumor-killing immune cells and to avoid the activation of immunosuppressive cells. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.


Insider Transactions at ALKS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
1.12M Shares
From 20 Insiders
Exercise of conversion of derivative security 776K shares
Grant, award, or other acquisition 341K shares
Sell / Disposition
846K Shares
From 19 Insiders
Payment of exercise price or tax liability 220K shares
Open market or private sale 626K shares

Track Institutional and Insider Activities on ALKS

Follow Alkermes plc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ALKS shares.

Notify only if

Insider Trading

Get notified when an Alkermes Plc. insider buys or sells ALKS shares.

Notify only if

News

Receive news related to Alkermes plc.

Track Activities on ALKS